Partnership aims to improve cost-to-deliver, compress timelines, strengthen compliance, and enable faster, evidence-backed decision-making across the clinical development lifecycle
Singapore, 09 April 2026
Expecto Health Science, a full-service Asia-Pacific Contract Research Organization (CRO), has entered into a strategic partnership with Neuratrial, an enterprise AI platform purpose-built for clinical research organizations, to jointly develop and implement an AI-enabled operating model across the clinical research lifecycle.
This partnership is aligned with Expectoโs strategic vision to evolve into a next-generation, AI-augmented CRO by embedding enterprise AI capabilities across critical functions, including feasibility, study start-up, clinical operations, medical writing, pharmacovigilance, regulatory documentation, and quality processes.
The collaboration will focus on deploying governed, enterprise-grade AI solutions tailored for clinical research workflows. These capabilities are expected to enhance operational efficiency, optimize timelines, strengthen audit readiness, and enable faster, data-driven decision-making across project lifecycles.
Expecto Health Science brings extensive expertise in end-to-end clinical development, regulatory strategy, project management, data management, and Functional Service Provider (FSP) delivery across the Asia-Pacific region. By integrating Neuratrialโs enterprise AI productivity layer, the partnership aims to establish a scalable and future-ready clinical delivery model that enhances speed, quality, compliance, and efficiency for sponsors.
Dr. Pramod Kashid, CEO of Expecto Health Science, stated:
“The clinical research landscape is undergoing a significant transformation driven by advancements in artificial intelligence. This partnership represents a strategic step towards building an AI-enabled CRO capable of delivering improved timelines, enhanced quality, and greater operational efficiency for sponsors.”
Pranab Pillai, Founder & CEO of Neuratrial, added:
“CROs and sponsors are under increasing pressure to accelerate study delivery while maintaining high-quality standards and cost efficiency. This collaboration is focused on enabling a next-generation operating model, where governed AI acts as a key enabler for clinical research teams.”
This strategic collaboration reflects a shared commitment by both organizations to advance clinical research through innovation, technology, and AI-enabled operating models, with the ultimate objective of accelerating the delivery of therapies to patients.
